Join us for our Gala Dinner, "Frontiers of Success: Honouring Excellence in Drug Innovation", featuring a delightful three-course meal and exceptional networking opportunities. Our venue will transform into a banqueting hall to celebrate the work and achievements of all our attendees in pushing the boundaries of discovery & development. Stay tuned to find out which esteemed figure will take the stage for an opening address!

Running on Day 1 and Day 2 afternoons of the event, this programme features 10-minute presentations from & exclusive panels with investors & collaborators of emerging biotech’s and academic spin-offs advancing drug discovery and development. Designed to boost visibility, attract partners, and secure funding, it connects innovators with pharma leaders, investors, solution providers, and mid-to-large biotech’s. Key sessions include:

Panel: Fostering Partnerships & Collaborations in 2025, with discussion around emerging technologies & techniques, cross-sector partnerships & open innovation. Hear insights from our esteemed panellists – Alexander Natz, Secretary General at EUCOPE; Lubor Gaal, CFO & CBO at Cicio Holdings; Anna-Pia Papageorgiou, Policy Officer at the European Commission & more!

A spotlight on investment initiatives – with key presentations on the BaseLaunch initiative from Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch & Virginia Ballotta, Manager of New Ventures, BaseLaunch & The Parkinsons Virtual Biotech by David Dexter, Director of Research, Parkinsons UK

Discovery Europe 2025

•  The ONE MERCK Bioconvergence Program To Help Transform Drug Discovery And Development While Reducing Animal Testing - Philip Hewitt, Global Head of Early Investigative Toxicology, Merck Healthcare
•  Using Data-Powered Translational Medicine To Design Better Drugs - Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis
•  Bridging The Gap Between Automation & Digitalisation Through FAIR & Digital Transformation - Rekha Lakshmanan, Global Head of Data Office, Astrazeneca
•  Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research - Moderator: Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford, Panellists: Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie, Sarah Jolly, Principal Scientist, LifeArc, Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London

Formulation & Delivery Europe 2025

With 150+ speakers representing large pharmaceutical companies, emerging biotechs & renowned academic institutions, we are proud to welcome over 45 award-winning experts across the 2 programmes:

• Shadi Farhangrazi, Chief Executive Officer of S.M. Discovery Group, received the 2018 BioInnovation Award for her work in drug discovery
•  Christoph Rösli, Director of Research Bern at CSL Behring, received the 2021 Swiss Biotech Success Stories Award for his contributions to biotechnology research.
•  Vineeta Tripathi, Chief Executive Officer of Vitarka Therapeutics, received the 2019 Women in Bio Entrepreneurial Leadership Award for her work in biotech entrepreneurship
•  Stephen Pham, Senior Vice President at Avalyn Pharma, was awarded the 2019 Respiratory Innovation Award
•  Emma Mead, Chief Scientific Officer at Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford, was honoured with the 2020 Alzheimer's Research UK Young Investigator of the Year Award for her work in neurodegenerative disease research.
•  Raul Rodriguez, Vice President at Woxsen University, received the 2021 Entrepreneur of the Year Award for his contributions to education in the biotech field.
•  Philip Hewitt, Global Head of Early Investigative Toxicology at Merck, was honoured with the Society of Toxicology's 2018 Achievement Award for his significant impact in toxicological research.